Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.43 |
| ▸ | CCR2 | P41597 | 9/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27260355 | 0.81 | NAMPT (0.51) | — | |
| SCHEMBL14619656 | 0.73 | DRD2 (0.60) | DRD2SIGMAR1 | |
| SCHEMBL24125410 | 0.72 | NAMPT (0.40) | — | |
| SCHEMBL27091798 | 0.72 | HDAC8 (0.55) | DRD2ADRA2ASIGMAR1 | |
| SCHEMBL24753371 | 0.69 | NAMPT (0.48) | — | |
| SCHEMBL3524057 | 0.68 | DRD2 (0.66) | DRD2SIGMAR1 | |
| SCHEMBL25031746 | 0.67 | DRD2 (0.55) | DRD2SIGMAR1 | |
| SCHEMBL6848549 | 0.67 | CCR2 (0.50) | DRD2CCR2ADRA2ASIGMAR1 | |
| SCHEMBL5510931 | 0.66 | DRD2 (0.60) | DRD2 | |
| SCHEMBL4572542 | 0.66 | DRD2 (0.60) | DRD2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026083-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |